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Abstract
Hereditary ataxias (HA) are a group of inherited neurological 
disorders caused by changes in genes. At least 115 different 
mutations in the senataxin (SETX) gene causing ataxia have 
been identified. There are no reports of any SETX gene mutation 
among the Iranian population. Here we report on two cases with 
homozygous and heterozygous mutations in which one patient 
was affected by HA with oculomotor apraxia type 2, and the other 
was a carrier of the disorder. In 2016, the affected patient was 
referred to the Biogene Medical and Genetic Laboratory (Tehran, 
Iran) suffering from imbalance and tremor of both head and body. 
The coding regions of 18 genes, including the SETX gene, were 
screened. The target regions were captured using the NimbleGen 
chip followed by next-generation sequencing (NGS) technology 
on the Illumina Hiseq2500 platform. NGS, a DNA sequencing 
technology, has greatly increased the ability to identify new 
causes of ataxia; a useful tool for the prevention of primary 
manifestations and treatment of affected patients. In the present 
study, a novel mutation in the SETX gene has been identified.
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What’s Known
• At least 115 different mutations in 
the senataxin (SETX) gene have been 
identified to cause ataxia.
• There are no reports of any SETX 
gene mutation among the Iranian 
population. 
What’s New
• A novel mutation, c.5268delT 
(p.Phe1756LeufsX30), in the SETX 
gene has been identified.
• For the first time, we report on two 
Iranian cases with SETX gene mutation 




The HA are a group of genetically and clinically heterogeneous 
disorders characterized by gradually progressive uncoordinated 
gait accompanied by poor hand coordination and speech 
impairment. Often, atrophy of the cerebellum occurs. Most affected 
individuals additionally have oculomotor apraxia, which impairs 
purposeful eye movement. Based on the Mendelian modes 
of inheritance, the HA are classified as autosomal recessive, 
autosomal dominant, and X-linked.1 They are caused by changes 
in the genes and can be inherited. HA are most often diagnosed 
through genetic testing by identifying the defective gene. Ataxia 
with oculomotor apraxia has been classified into several types, 
among which types 1, 2, and 4 are the most common.2 Although 
the types are very similar, they are caused by mutations of 
different genes. Here we report HA with oculomotor apraxia type 
2 caused by a pathogenic mutation in the SETX gene.
Case Presentation
The first case was a 24-year-old male patient suffering from 
imbalance and tremor of both head and body. The patient 
was referred to our clinic in the Biogene Medical and Genetic 
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Laboratory, Tehran, Iran. A magnetic resonance 
imaging (MRI) scan was performed and probable 
ataxia with oculomotor apraxia was diagnosed. 
Subsequently, DNA analysis was performed to 
determine the genetic status of the patient. After 
obtaining a written informed consent, his DNA was 
extracted from peripheral blood cells using the 
standard method. Genetic analysis was performed 
on 18 genes, including KCNA1, CACNA1A, 
CACNB4, SLC1A3, VAMP1, APTX, SETX, and 
PNKP. The target regions were captured using the 
NimbleGen chip on the genes of interest followed 
by NGS on the Illumina Hiseq2500 platform. The 
second case, a carrier of HA, was a 36-year-old 
asymptomatic man who was a blood relative of 
the affected patient. He voluntarily participated 
in laboratory analysis and his DNA was extracted 
from peripheral blood cells using the standard 
method. The DNA was subjected to genetic 
analysis for the SETX gene using the polymerase 
chain reaction (PCR) DNA sequencing method.
Neurological examination of the affected 
patient revealed dysarthria, bilaterally restricted 
upward and lateral eye movements, limb and 
gait ataxia. The onset of his symptoms was at 
the age of 20. The MRI of his head revealed 
cerebellar atrophy (figure 1). DNA analysis 
showed a pathogenic mutation, c.5268delT 
(p.Phe1756LeufsX30), in the SETX gene in a 
homozygous state (figure 2). Additionally, the 
result of the BLAST analysis revealed that the 
deleted nucleotide was a type T on the site of 
5468 in SETX mRNA. SETX-related ataxia with 
oculomotor apraxia type 2 was inherited in an 
autosomal recessive manner. Mutation detection 
in parent cells showed the heterozygote 
status of this mutation. The same SETX gene 
mutation, c.5268delT (p.Phe1756LeufsX30), in 
heterozygous status was detected in the second 
case (figure 2). Therefore, he was a carrier of 
the familial mutation. The family pedigree of the 
patient is depicted in figure 3.
Discussion
The HA are a genetically heterogeneous group 
of disorders which are difficult to separate 
clinically as they are all diagnosed with poor 
motor coordination arising from a malfunction of 
the cerebellum and its connections.3 Based on 
the Mendelian modes of inheritance, the HA are 
classified as autosomal recessive, autosomal 
dominant, and X-linked.1 The prevalence of 
the autosomal dominant cerebellar ataxias is 
reported to be 1-5:100,000 population. The 
prevalence of the autosomal recessive type of 
HA is roughly estimated to be 3:100,000 with 
ataxia-telangiectasia, Friedreich ataxia, and 
Figure 1: Brian MRI of the proband with cerebellar atrophy.
Figure 2: The DNA sequence of the SETX gene in the 
affected patient with the frameshift mutation, c.5268delT 
(p.Phe1756LeufsX30), in homozygous state (A). Mutation 
confirmation by reverse primer (B). The DNA sequence of the 
SETX gene in the second case showing the same mutation 
in heterozygous status (C).
Figure 3: Family pedigree of the cases (affected patient and 
the carrier of HA).
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ataxia with oculomotor apraxia being the most 
frequent.4 HA are caused by changes in the 
genes and can be inherited.1
Mutations in the APTX, SETX, and PNKP 
genes result in ataxia with oculomotor apraxia 
types 1, 2, and 4, respectively. These genes 
provide instructions for the production of 
proteins that are involved in repairing damaged 
DNA. Mutations in any of these genes reduce 
the amount of produced functional proteins. 
The lack of functional proteins disrupts DNA 
repair and can lead to the accumulation of DNA 
damage in cells, particularly affecting brain cells 
in the part of the brain involved in coordinating 
movements (the cerebellum).5-8 
At least 115 different SETX gene mutations 
causing ataxia have been identified.9 Most 
mutations replace single amino acids in the 
SETX gene. There are no reports of any SETX 
gene mutation among the Iranian population. For 
the first time, we have reported two Iranian cases 
with homozygous and heterozygous mutations 
in which one was affected and the other was a 
carrier of HA with oculomotor apraxia type 2. 
In the present study, we identified a novel 
mutation [c.5268delT (p.Phe1756LeufsX30)]. 
Bioinformatics tools such as SIFT, PolyPhen-2, 
and Project Hope predicted this mutation to be 
a deleterious mutation. This frameshift mutation 
causes an early termination of the amino acid 
coding, which affects the protein’s function. 
Genetic diagnosis is routinely performed by 
sequence analysis of candidate genes to confirm 
previously identified mutations. NGS of the DNA 
using gene panels enabled us to simultaneously 
examine coding regions and splice-junctions of 
several candidate genes. It shortened the duration 
of the analysis which was not only beneficial in 
the treatment, but also in the prenatal diagnosis 
and carrier detection of the disease.
Conclusion
Due to the diversity of symptoms and various 
genetic causes of ataxia, clinicians and 
geneticists are faced with a diagnostic challenge. 
Advancement in DNA sequencing technology (e.g., 
NGS) has greatly increased our ability to identify 
new causes of ataxia, which can be effective in 
the prevention of primary manifestations and 
treatment of the affected patients. 
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